Incidences of inflammatory bowel disease (IBD) and of breast cancer have increased over the last decades.
The influence of inflammatory bowel disease on breast cancer prognosis, however, is unknown.
Dr Kirstine Kobberøe Søgaard and colleagues from Denmark examined the impact of inflammatory bowel disease on treatment receipt and survival in breast cancer patients.
|Chemotherapy was associated with poorer survival in patients with Crohn's|
|Inflammatory Bowel Diseases|
The team found information on breast cancer patients diagnosed between 1980 and 2004, sourced from the Danish Cancer Registry.
Data on inflammatory bowel disease and potential confounders were extracted from the Danish National Registry of Patients covering all Danish hospitals.
The team used cox regression to compute mortality rate ratios among breast cancer patients with inflammatory bowel disease.
The research team then compared these rates to their non-inflammatory bowel disease counterparts.
The researchers adjusted for age, stage, comorbidity measured by the Charlson Index, and calendar year.
The team identified 71,148 breast cancer cases, of which 67 also had Crohn's disease and 216 had ulcerative colitis.
Patients with Crohn's disease had more advanced stage and received radiotherapy less, and chemotherapy more, frequently than patients without inflammatory bowel disease.
The researchers found that in the adjusted analyses there was no substantial survival difference in breast cancer patients with and without inflammatory bowel disease.
The team noted that in a stratified analysis, chemotherapy was associated with poorer survival in patients with Crohn's disease.
Dr Kobberøe Søgaard's team concluded, "Breast cancer patients with ulcerative colitis receive the same treatment and have similar survival to breast cancer without inflammatory bowel disease."
"In contrast, breast cancer patients with Crohn's disease are treated with radiotherapy less often."
"Survival of breast cancer in patients with Crohn's disease treated with chemotherapy is poorer compared to survival in patients without inflammatory bowel disease."